Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

NewAmsterdam Pharma Company N.V. - Ordinary Shares (NQ: NAMS )

17.12 +0.94 (+5.81%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 319,330
Open 16.21
Bid (Size) 16.60 (1)
Ask (Size) 17.93 (1)
Prev. Close 16.18
Today's Range 15.85 - 17.45
52wk Range 5.633 - 26.35
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Analyst Confident In NewAmsterdam Pharma's Cholesterol Drug Despite Mixed Reactions To Study Results
NewAmsterdam Pharma announced positive topline results from the Phase 3 BROOKLYN trial for obicetrapib, showing a significant LDL-C reduction in HeFH patients. The stock fell 8.35% despite the success,... 
Via Benzinga
Abbott, Integra LifeSciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga

Performance

YTD
+43.26%
+43.26%
1 Month
-16.81%
-16.81%
3 Month
-21.50%
-21.50%
6 Month
-14.14%
-14.14%
1 Year
+48.61%
+48.61%

More News

Read More
NewAmsterdam Touts Cholesterol Drug Success, But Results Trail Analysts' Expectations
Via Investor's Business Daily
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
Via Investor's Business Daily
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark Office
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
From NewAmsterdam Pharma N.V
Via GlobeNewswire
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
From NewAmsterdam Pharma N.V
Via GlobeNewswire
NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress
From NewAmsterdam Pharma N.V
Via GlobeNewswire
NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD
From NewAmsterdam Pharma N.V
Via GlobeNewswire
NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update
From NewAmsterdam Pharma N.V
Via GlobeNewswire
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March
From NewAmsterdam Pharma N.V
Via GlobeNewswire
NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
From NewAmsterdam Pharma N.V
Via GlobeNewswire
NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
From NewAmsterdam Pharma N.V
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.